Renal denervation in patients with end-stage renal disease and resistant hypertension on long-term haemodialysis
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Introduction: Recent randomized controlled trials have confirmed the ability of renal denervation to lower blood pressure (BP) in patients, resistant to the BP-lowering effect of multiple antihypertensive drug administration. Evidence is limited, however, in patients with end-stage renal disease (ESRD) and haemodialysis, a condition in which a persistent BP elevation, despite administration of many antihypertensive drugs, is common. Aim of the present study was to test the BP-lowering efficacy of renal denervation in patients with resistant hypertension and ESRD on haemodialysis. BP was measured repeatedly in the office and over the 24 h during 1-year follow-up. Methods and results: The study was conducted from February 2017 to January 2018 at the Policlinico of Monza, Monza, Italy. We included 24 men and women aged at least 20 years (mean 55 ± 16) who had ESRD, were on long-term haemodialysis and exhibited resistant hypertension, that is, elevated office and ambulatory BP values, despite multidrug antihypertensive treatment ( n = 5.4 ± 1). We excluded patients with renal artery stenosis, malignancy, and a probable life expectancy less than 1 year. Twelve patients were included in the renal denervation and 12 in the medical treatment (control) group. All patients underwent office and 24 h ambulatory BP measurements at baseline and at 1, 6 and 12 months during the follow-up. In the renal denervation group, baseline office and 24 h mean SBP were 180 ± 112 and 175 ± 11 mmHg, respectively, the corresponding values in the control group being 181 ± 19 and 181 ± 20 mmHg. Most of the other baseline characteristics were also similar or only slightly different between groups, including the mean number of administered antihypertensive drugs at baseline. SBP showed an early and persistent reduction after renal denervation (office SBP: 165 ± 13; 150 ± 7 and 149 ± 11mmHg; 24 h SBP 163 ± 20, 148 ± 10 and 149 ± 17 mmHg after 1, 6 and 12 months, respectively). The BP-lowering effect was almost always present and statistically significant during both the day and night. DBP changes followed a similar pattern whereas heart rate never showed any significant change. No significant periprocedural complication of renal denervation was seen. The mean number of administered drugs did not show any significant BP change during the study. Conclusion: In ESRD patients under long-term haemodialysis in whom BP was markedly elevated despite administration of many antihypertensive drugs, renal denervation lowered both ambulatory and office BP. The reduction persisted over a 1-year follow-up.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this sham-controlled trial, which included 24 patients with kidney failure on long-term haemodialysis, radiofrequency RDN led to a sustained decrease in 24-h ambulatory systolic blood pressure (SBP) that persisted over a 1-year follow-up period64.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [64]
In the citing paper
“a small clinical trial in 24 patients with kidney failure on haemodialysis confirmed the safety of the procedure in these patients and demonstrated that RDN resulted in significant reductions in DBP and SBP that persisted for at least 12 months64.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [64]
Citations
Cites
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Self-citationA Controlled Trial of Renal Denervation for Resistant Hypertension
Bhatt, D. L., Kandzari, D. E., O'Neill, W. W., D'Agostino, R., Flack, J. M., Katzen, B. T., Leon, M. B., Liu, M., Mauri, L., Negoita, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402670 · Cited by 2,186
Kandzari, D. E., Böhm, M., Mahfoud, F., Townsend, R. R., Weber, M. A., Pocock, S., Tsioufis, K., Tousoulis, D., Choi, J. W., East, C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30951-6 · Cited by 793
Townsend, R. R., Mahfoud, F., Kandzari, D. E., Kario, K., Pocock, S., Weber, M. A., Ewen, S., Tsioufis, K., Tousoulis, D., Sharp, A. S. P., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32281-x · Cited by 752
Azizi, M., Schmieder, R. E., Mahfoud, F., Weber, M. A., Daemen, J., Davies, J., Basile, J., Kirtane, A. J., Wang, Y., Lobo, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31082-1 · Cited by 740
The Sympathetic Nervous System Alterations in Human Hypertension
Grassi, G., Mark, A., & Esler, M. (2015) · Circulation Research · doi:10.1161/circresaha.116.303604 · Cited by 616 · cited 2×
“Although additional mechanisms are probably involved [9,10], the BP-lowering effect is primarily explained by the fact that (1) hypertension is accompanied by a hyperactivity of the sympathetic nervous system, which becomes progressively more marked as hypertension becomes more severe [11], and reaches a maximum in re…”
BackgroundSelf-citationAzizi, M., Sapoval, M., Gosse, P., Monge, M., Bobrie, G., Delsart, P., Midulla, M., Mounier-Véhier, C., Courand, P.-Y., Lantelme, P., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61942-5 · Cited by 519
Zoccali, C., Mallamaci, F., Parlongo, S., Cutrupi, S., Benedetto, F. A., Tripepi, G., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., et al. (2002) · Circulation · doi:10.1161/hc1102.105261 · Cited by 519 · cited 1×
“In these patients, however, renal denervation might represent a potentially beneficial intervention as the sympathetic activation associated with hypertension (1) becomes progressively greater with the progression of renal damage (reaching a maximum in ESRD [16]), (2) persists after renal transplantation [14], (3) is…”
BackgroundThe Structural Factor of Hypertension: Large and Small Artery Alterations
Laurent, S., & Boutouyrie, P. (2015) · Circulation Research · doi:10.1161/circresaha.116.303596 · Cited by 488 · cited 1×
“This progressive sympathetic inactivation may have progressively reduced the sympathetic trophic influences on arteriolar walls with a slow progressive reduction in peripheral vascular resistance [23,24].”
BackgroundAgarwal, R., Nissenson, A. R., Batlle, D., Coyne, D. W., Trout, J. R., & Warnock, D. G. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00366-8 · Cited by 480 · cited 1×
“It is also relevant that in patients with ESRD and dialysis, BP elevation is common and its control by multiple drug treatment is particularly difficult [19].”
Background
Cited by
Hypertension management in patients with cardiovascular comorbidities
Lauder, L., Mahfoud, F., Azizi, M., Bhatt, D. L., Ewen, S., Kario, K., Parati, G., Rossignol, P., Schlaich, M. P., Teo, K. K., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac395 · Cited by 210
Diagnosis and treatment of arterial hypertension 2021
Ott, C., & Schmieder, R. E. (2021) · Kidney International · doi:10.1016/j.kint.2021.09.026 · Cited by 151
Rey-García, J., & Townsend, R. R. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.03.015 · Cited by 74
“4 BP-lowering medications.(40) RDN was associated with a significant BP-lowering effect.”
BackgroundRenal nerves in physiology, pathophysiology and interoception
Evans, L. C., Dayton, A., & Osborn, J. W. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00893-3 · Cited by 46
“In this sham-controlled trial, which included 24 patients with kidney failure on long-term haemodialysis, radiofrequency RDN led to a sustained decrease in 24-h ambulatory systolic blood pressure (SBP) that persisted over a 1-year follow-up period 64 .”
Xia, M., Liu, T., Chen, D., & Huang, Y. (2021) · International Journal of Hyperthermia · doi:10.1080/02656736.2021.1916100 · Cited by 41
Metadata
- Authors
- Scalise, F., Sole, A., Singh, G., Sorropago, A., Sorropago, G., Ballabeni, C., Maccario, M., Vettoretti, S., Grassi, G., & Mancia, G.
- Affiliations
- European Society of Hypertension (IT)
- Department of Interventional Cardiology
- Azienda Ospedaliera San Gerardo (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- University of Milano-Bicocca (IT)
- Corresponding author
- Mancia, Giuseppe
- ORCID
- Venue
- Journal of Hypertension
- Published
- 2020-05
- Volume
- 38
- Issue
- 5
- Pages
- 936-942
- ISSN
- 0263-6352 (ISSN-L)
- 1473-5598
- OpenAlex
- W3003298643
- Cited by
- 42
- References
- 42
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 7 · 2023: 7 · 2022: 2 · 2021: 7 · 2020: 3
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hypertension (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- renal denervation, resistant hypertension, end-stage renal disease, hemodialysis, blood pressure reduction, ambulatory blood pressure, antihypertensive therapy, renal sympathetic nerves
- MeSH terms
- Adult, Aged, Antihypertensive Agents, Blood Pressure, Denervation, Female, Heart Rate, Renal Dialysis, Humans, Hypertension, Italy, Kidney, Kidney Failure, Chronic, Male, Middle Aged, Treatment Outcome, Blood Pressure Monitoring, Ambulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Renal denervation in patients with end-stage renal disease and resistant hypertension on long-term haemodialysis. https://app.cochat.ai/papers/10.1097/hjh.0000000000002358
- The paper
- Scalise, F., Sole, A., Singh, G., Sorropago, A., Sorropago, G., Ballabeni, C., Maccario, M., Vettoretti, S., Grassi, G., & Mancia, G. (2020). Renal denervation in patients with end-stage renal disease and resistant hypertension on long-term haemodialysis. Journal of Hypertension. https://doi.org/10.1097/hjh.0000000000002358
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.